Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23281864 | 0.89 | AAK1 (0.37) | AAK1RXFP1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2768352 | 0.85 | CA12 (0.39) | RXFP1RAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL29588945 | 0.84 | HSP90AA1 (0.38) | RXFP1RAB9ANPC1SMN1; SMN2CYP17A1 | |
| SCHEMBL22531782 | 0.84 | HSP90AA1 (0.38) | RXFP1RAB9ANPC1SMN1; SMN2CYP17A1 | |
| SCHEMBL38664265 | 0.82 | RAB9A (0.34) | RXFP1RAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL31488142 | 0.80 | RXFP1 (0.57) | RXFP1RAB9ANPC1HTTCA1 | |
| SCHEMBL25593892 | 0.78 | PTPRC (0.41) | AAK1RXFP1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL29901136 | 0.78 | RXFP1 (0.39) | RXFP1RAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL593484 | 0.77 | RXFP1 (0.62) | AAK1RXFP1RAB9ANPC1MEN1 | |
| SCHEMBL29926665 | 0.76 | JAK2 (0.46) | RXFP1HTTCA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174648-A1 | Small Molecule Compound | TECHNODERMA MEDICINES INC. (CN) | 2024-05-30 | — | — | US | disclosed |
| US-7834049-B2 | Sulfonamide compound for treating arteriosclerosis, psoriasis, colon cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | WAKABAYASHI TOSHIAKI | 2010-10-21 | — | — | US | disclosed |
| EP-1258252-B1 | INTEGRIN EXPRESSION INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2010-04-21 | — | — | EP | disclosed |
| CN-100356979-C | Integrin expression inhibitors | EISAI CO LTD (JP) | 2007-12-26 | — | — | CN | disclosed |
| US-20050176712-A1 | Integrin expression inhibitor | EISAI CO., LTD. | 2005-08-11 | — | — | US | disclosed |
| US-20040018192-A1 | Integrin expression inhibitors | EISAI CO., LTD. (JP) | 2004-01-29 | — | — | US | disclosed |
| US-6673787-B2 | PYRIMIDINESULFONAMIDE CONTAINING INDOLE COMPOUNDS USED AS ANTIANGIOGENIC AND ANTITUMOR AGENTS | EISAI CO., LTD. (JP) | 2004-01-06 | — | — | US | disclosed |
| CN-1132814-C | Sulfonamide-containing indole compounds | EISAI CO.,LTD. (JP) | 2003-12-31 | — | — | CN | disclosed |
| US-6638964-B2 | Pyridinesulfonamide containing indole compounds used as antiangiogenic and antitumor agents | EISAI CO., LTD. (JP) | 2003-10-28 | — | — | US | disclosed |
| CN-1396833-A | Integrin expression inhibitors | EISAI CO LTD (JP) | 2003-02-12 | — | — | CN | disclosed |
| EP-1258252-A1 | INTEGRIN EXPRESSION INHIBITORS | Eisai Co., Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
| US-6469043-B1 | ANTIANGIOGENIC AGENT WITH ANTITUMOR, ANTIMETASTATIC PROPERTIES WHICH SHOWS HIGH SAFETY | EISAI CO., LTD. (JP) | 2002-10-22 | — | — | US | disclosed |
| US-20020128483-A1 | Sulfonamide-containing indole compounds | EISAI CO., LTD. | 2002-09-12 | — | — | US | disclosed |
| US-20020128480-A1 | Sulfonamide-containing indole compounds | EISAI CO., LTD. | 2002-09-12 | — | — | US | disclosed |
| CN-1294579-A | Sulfonamide-containing indole compounds | EISAI CO LTD (JP) | 2001-05-09 | — | — | CN | disclosed |
| EP-1074542-A1 | SULFONAMIDE-CONTAINING INDOLE COMPOUNDS | Eisai Co., Ltd. (JP) | 2001-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176712-A1 | Integrin expression inhibitor | ITGB5, ITGB1, ITGB2 | AAK1 4043/4885RXFP1 1804/4885RAB9A 1119/4885 |
| US-20020128480-A1 | Sulfonamide-containing indole compounds | IDO1, HCCS, VEGFA | AAK1 1710/4885RXFP1 158/4885RAB9A 2411/4885 |
| US-20240174648-A1 | Small Molecule Compound | JAK1, JAK2, TYK2 | AAK1 224/4885RXFP1 581/4885RAB9A 2519/4885 |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | ITGB5, ITGB1, ITGB2 | AAK1 4043/4885RXFP1 1804/4885RAB9A 1119/4885 |
| US-20020128483-A1 | Sulfonamide-containing indole compounds | IDO1, HCCS, VEGFA | AAK1 1675/4885RXFP1 149/4885RAB9A 2447/4885 |
| US-20040018192-A1 | Integrin expression inhibitors | ITGB1, ITGB4, ITGB5 | AAK1 3895/4885RXFP1 2141/4885RAB9A 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.